Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 6;11(1):69.
doi: 10.1038/s41531-025-00919-y.

Application of new biologic disease criteria for synucleinopathies to the systemic synuclein sampling study cohort

L M Chahine  1 , M C Brumm  2 , A R Nair  2 , S Mosovsky  3 , N K Polinski  4 , T G Beach  5 , B Mollenhauer  6 , C H Adler  7 ; Systemic Synuclein Sampling Study
Collaborators, Affiliations

Application of new biologic disease criteria for synucleinopathies to the systemic synuclein sampling study cohort

L M Chahine et al. NPJ Parkinsons Dis. .

Abstract

We applied biologic criteria and NSD-ISS to Synuclein Sampling Study, a PD sample with range of durations since clinical diagnosis. 93% of evaluable participants met biologic criteria. The majority were NSD-ISS stage3 or less, including >40% of the advanced PD group. Interpretation of staging in medicated patients is challenging. Biologic criteria and clinico-biomarker staging are important steps forward, but quantitative biomarkers of disease progression, not influenced by medications, are critically needed.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. Dam, T. et al. Neuronal alpha-synuclein disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts. NPJ Parkinsons Dis.10, 178 (2024). - PMC - PubMed
    1. Simuni, T. et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol.23, 178–190 (2024). - PubMed
    1. Höglinger, G. U. et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol.23, 191–204 (2024). - PubMed
    1. Visanji, N. P. et al. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson’s disease. Biomark. Med.11, 359–368 (2017). - PubMed
    1. Chahine, L. M. et al. In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology95, e1267–e1284 (2020). - PMC - PubMed

LinkOut - more resources